Curated News
By: NewsRamp Editorial Staff
July 31, 2025
Soligenix's SGX945 Shows Promise in Behçet’s Disease Treatment
TLDR
- Soligenix's SGX945 shows a 40% improvement in Behçet’s Disease treatment, offering a competitive edge in rare disease therapeutics with potential for broader application.
- SGX945 demonstrated biological efficacy in a Phase 2a study, with 7 of 8 patients showing reduced ulcer duration, number, and pain, supporting further development.
- Advancing SGX945 could significantly improve the quality of life for Behçet’s Disease patients, addressing a critical unmet need in rare disease treatment.
- Soligenix's breakthrough with SGX945 in Behçet’s Disease highlights the potential of innate immune regulation to transform treatment for inflammatory conditions.
Impact - Why it Matters
This news is significant for patients suffering from Behçet’s Disease and other rare inflammatory conditions, offering hope for more effective treatments. The success of SGX945 could lead to improved quality of life for affected individuals and represents a notable advancement in biopharmaceutical research. Additionally, Soligenix's broader portfolio, including potential vaccines for COVID-19 and other infectious diseases, highlights the company's role in addressing pressing global health challenges.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, has announced promising results from its Phase 2a proof of concept study for SGX945 (dusquetide) in treating Behçet’s Disease. The study demonstrated a significant 40% improvement in the primary ulcer endpoint compared to a historical placebo group, with seven out of eight patients reporting reduced ulcer duration, number, and pain. These results, which matched or exceeded those of apremilast (Otezla(R)), were achieved despite the treatment period being limited to four weeks. CEO Christopher J. Schaber highlighted the potential of SGX945, including plans for reformulation for home-based subcutaneous administration, to address unmet needs in Behçet’s and other inflammatory conditions. For more details, visit the full press release.
Soligenix is also advancing other innovative therapies, including HyBryte(TM) for cutaneous T-cell lymphoma and vaccine candidates for diseases like COVID-19, leveraging its ThermoVax(R) technology. Supported by government grants, the company's efforts in both rare diseases and public health solutions underscore its commitment to addressing critical healthcare challenges. Learn more about their groundbreaking work at www.Soligenix.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Soligenix's SGX945 Shows Promise in Behçet’s Disease Treatment
